5-α reductase inhibitors, Androgen antagonists, BCG, BCG therapy, BCG-unresponsive disease, Bladder neoplasms, Bladder-sparing therapy, Bladder-sparing trimodality, Chemoradiotherapy, Clinical pathways, Clinical staging, Collaborative care, Comorbidity, Cystectomy, Early recurrence patterns, EORTC, ERBB2, ERCC2, Gene expression analysis, Guidelines, Hematuria, High-risk NMIBC, Immune checkpoint, Immune checkpoint blockade, Immunoregulation, Immunotherapy, Intravesical therapy, Laparoscopic radical cystectomy, Meta-analysis, Metastatic urothelial cancer, MIBC, Molecular subtypes, Multiparametric MRI, Neoadjuvant, Neoadjuvant chemotherapy, Neoplasm recurrence, NIBC, Nuclear matrix protein 22, Oncologic outcomes, Open radical cystectomy, Optical coherence, PD-L1, Pembrolizumab, PET, PLND, Postoperative complications, POUT trial, Prevention & control, Quality of life, Radical cystectomy, Radio-chemotherapy, Randomized controlled trial, RARC, RAZOR Trial, Recurrence, Robotic, Robotic prostatectomy, Robotic radical cystectomy, Robotic surgery, Surgical video, Systematic review, Tomography, Transitional cell, Transitional cell carcinoma, Tregs, Urinary bladder neoplasms, Urinary diversion, Urological surgery, Urothelial cancer